9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Estimated reading time: < 1 min

Condition: B-cell Acute Lymphoblastic Leukemia

Estimated Enrollment: 73

Gender: All

Min Age: 4 Years

Age Group: Child, Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Number of Participants With Adverse Events evaluated with NCI CTC AE, version 4.0,  Clinical response,  CAR-T cells testing,

Interventions: CAR-T cell immunotherapy,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 1, 2023

Completion Date: March 1, 2023

Last  Posted Date: August 20, 2018

Location: The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Website Link: https://ClinicalTrials.gov/show/NCT03638206

Was this article helpful?
Dislike 0